Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Immix Biopharma’s SEC disclosures often means scrolling through patent tables, multi-arm trial protocols and complex licensing clauses—information you need, but buried in hundreds of pages. If you have ever searched for “Immix Biopharma insider trading Form 4 transactions” or struggled to locate the latest oncology trial costs in a 10-K, you know the challenge.
Stock Titan solves that problem. Our AI instantly converts every Immix Biopharma quarterly earnings report 10-Q filing, 8-K material event, and proxy statement into clear language, highlighting where cash burn is trending and which milestones trigger future funding. With real-time EDGAR feeds, you receive Immix Biopharma Form 4 insider transactions real-time alerts, plus side-by-side charts that explain dilution risk and clinical spend—no spreadsheet gymnastics required.
Use this page to:
- Scan Immix Biopharma annual report 10-K simplified summaries to understand pipeline progress and orphan-drug incentives.
- Dive into Immix Biopharma 8-K material events explained for rapid updates on FDA designations and capital raises.
- Monitor Immix Biopharma executive stock transactions Form 4 before pivotal data read-outs.
- Read Immix Biopharma earnings report filing analysis that connects trial expenses to runway forecasts.
Whether you are comparing CAR-T competitors or simply understanding Immix Biopharma SEC documents with AI, our platform keeps every filing accessible, searchable, and context-rich—so you can focus on making informed biotech decisions, not deciphering legalese.
Form 4 Filing Details for Immix Biopharma (IMMX) reveals insider trading activity by Director Magda Marquet on June 20, 2025. The transaction involves the following key details:
- Acquisition of 33,000 stock options with exercise price of $2.24 per share
- Options expire on June 20, 2035
- Vesting schedule: 12 equal monthly installments from grant date
- Current holdings: 46,092 shares held directly and 20,000 shares held indirectly through ALMA Life Sciences, LLC
This stock option grant appears to be part of the company's director compensation program. The options provide Marquet with the right to purchase IMMX shares at $2.24 through 2035, aligning the director's interests with long-term shareholder value.
On 06/20/2025, Immix Biopharma (IMMX) director Jason Hsu filed a Form 4 disclosing a single insider transaction. The company issued Hsu a stock option covering 33,000 shares with a strike price of $2.24 per share. The option vests in twelve equal monthly installments from the grant date and expires on 06/20/2035, conditional on his continued service on the board.
After the award, Hsu reports total beneficial ownership of 4,861,913 common shares, broken down as: 893,000 shares held directly; 3,915,913 shares indirectly through Veritas Liberabit Vos, LLC; and 50,000 shares indirectly through Signature Collection Properties, LLC. No sales or dispositions occurred in this filing.
The incremental 33,000-share option grant represents less than 1 % of Hsu’s existing stake and does not materially alter the company’s capital structure. While the transaction reinforces management-shareholder alignment, its small size suggests limited immediate market impact.
Helen C. Adams, Director of Immix Biopharma (IMMX), reported the following insider trading activity on June 28, 2025:
- Received a stock option grant to purchase 33,000 shares of common stock at an exercise price of $2.24 per share
- The options were granted on June 20, 2025, with an expiration date of June 20, 2035
- Vesting schedule: Equal monthly installments over 12 months, contingent on continued board service
- Currently holds 174,754 shares of common stock directly
This Form 4 filing reflects standard board compensation practices through equity grants. The transaction was executed pursuant to the company's director compensation program, with the options granted at fair market value.
Immix Biopharma, Inc. (IMMX) – Form 4 insider filing dated 06/23/2025
Director Jane Buchan reported one equity award and updated share ownership as of 06/20/2025:
- New derivative grant: 33,000 non-qualified stock options with an exercise price of $2.24 per share, expiring 06/20/2035. The options vest in 12 equal monthly installments beginning on the grant date, contingent on continued service (Note 1).
- Post-transaction ownership: 22,455 shares of common stock held directly. No common shares were bought or sold in the reported period; the table only updates the total beneficial ownership.
No cash consideration was paid for the option grant (price listed as $0.00), indicating a routine director compensation award. The filing does not disclose any simultaneous open-market transactions, earnings data, or major corporate events.
Investors should note that while option grants can create future dilution if exercised, the 33,000-share award is relatively small and vests over one year, spreading potential dilution. The filing aligns the director’s incentives with shareholder value but, by itself, does not signal immediate changes to Immix Biopharma’s financial outlook.
Immix Biopharma, Inc. (IMMX) – Form 4 filed 06/23/2025
The filing discloses one transaction by Director and 10% owner Yekaterina (Katie) Chudnovsky dated 06/20/2025. She received a stock-option grant for 33,000 shares of common stock with an exercise price of $2.24 per share and an expiration date of 06/20/2035. The option vests in twelve equal monthly installments, contingent on continued board service. The option was acquired at no cost (transaction code “A”).
No non-derivative shares were bought or sold; the filing merely repeats her existing indirect ownership of 3,241,076 common shares held through GKCC, LLC, of which she is the sole member and manager. After the reported transaction, her total beneficial holdings stand at 3,241,076 shares (indirect) plus 33,000 derivative securities (direct).
Overall, the filing signals continued alignment between the director and shareholders through a sizeable existing stake and modest additional option incentives. The transaction does not materially alter the company’s share count or insider ownership structure.
Form 4 overview: Immix Biopharma, Inc. (ticker: IMMX) filed a Form 4 reporting an open-market purchase by Chief Financial Officer and Director Gabriel S. Morris on 18 June 2025.
- Transaction details: Mr. Morris bought 2,225 common shares at a volume-weighted average price of $2.279 per share (code “P”).
- Direct ownership after transaction: 288,059 common shares held in his own name (ownership code “D”).
- Indirect ownership: 270,844 shares held through Alwaysraise LLC and 24,141 shares held through Alwaysraise Ventures I LP (ownership code “I”). For both entities, Mr. Morris disclaims beneficial ownership except to the extent of his pecuniary interest.
- No derivative securities were reported in Table II.
- The filing was electronically signed by Mr. Morris on 20 June 2025.
The Form 4 reflects Mr. Morris’ latest equity position and provides investors with an updated view of insider holdings as of 18 June 2025.
FAQ
What is the current stock price of Immix Biopharma (IMMX)?
What is the market cap of Immix Biopharma (IMMX)?
